Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| IPSC | PRESS-RELEASE | bullish | 4/10 | Century Therapeutics presented preclinical data for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diab | Oct 2, 2026 |
| ACIU | 6-K | neutral | 2/10 | AC Immune SA held an Extraordinary General Meeting on October 2, 2026, where shareholders approved the election of Tom G | Oct 2, 2026 |
| CNSP | 8-K | neutral | 3/10 | CNS Pharmaceuticals held its 2026 Annual Meeting on September 30, 2026, where stockholders approved an amendment to the | Oct 2, 2026 |
| TEVA | PRESS-RELEASE | bullish | 5/10 | Teva announced a peer-reviewed publication in the Journal of Child Neurology summarizing the neurobiological rationale a | Oct 2, 2026 |
| TEVA | PRESS-RELEASE | bullish | 6/10 | Teva presented new Phase 2b/3 and open-label extension data for ecopipam (D1 antagonist) in pediatric Tourette syndrome | Oct 2, 2026 |
| SRZN | PRESS-RELEASE | bullish | 6/10 | Surrozen received FDA clearance to begin clinical trials of SZN-8141 for diabetic macular edema, a key pipeline mileston | Oct 2, 2026 |
| QNCX | DEFA14A | neutral | 5/10 | Quince Therapeutics filed a DEFA14A supplement to its proxy statement, announcing that three directors (June Bray, David | Oct 2, 2026 |
| QNCX | 8-K | neutral | 3/10 | Three directors (June Bray, David Lamond, Christopher Senner) tendered conditional resignations effective after the Octo | Oct 2, 2026 |
| IFRX | PRESS-RELEASE | neutral | 3/10 | InflaRx announced that its oral C5aR1 antagonist izicopan was selected for a late-breaking poster at ASN Kidney Week 202 | Oct 2, 2026 |
| PYXS | PRESS-RELEASE | bearish | 7/10 | Pyxis Oncology closed a ~$110M public offering on October 1, 2026, selling 36M shares and pre-funded warrants for 1.9M s | Oct 2, 2026 |
| AZN | 6-K | neutral | 5/10 | AstraZeneca and Daiichi Sankyo entered a clinical collaboration with Summit Therapeutics to evaluate Datroway (datopotam | Oct 2, 2026 |
| ABT | ANALYST-UPGRADE | mixed | 3/10 | Rothschild & Co double-upgraded ABT (ABBOTT LABORATORIES) from Neutral to Buy on October 2, 2026, raising the price targ | Oct 2, 2026 |
| ADXN | 6-K | neutral | 3/10 | Addex Therapeutics announced executive management changes: Jean-Philippe Rocher appointed Head of Pharmaceutical Develop | Oct 2, 2026 |
| TPST | EFFECT | bearish | 6/10 | The SEC declared effective Tempest Therapeutics' S-3 registration statement (File No. 333-299142) on October 1, 2026, en | Oct 2, 2026 |
| INM | EFFECT | neutral | 3/10 | InMed Pharmaceuticals Inc. received SEC effectiveness on October 1, 2026, for its S-4 registration statement (File No. 3 | Oct 2, 2026 |
| LEXX | S-3 | bearish | 5/10 | Lexaria Bioscience Corp. filed an S-3 registration statement to register up to 923,827 shares of common stock for resale | Oct 1, 2026 |
| HELP | 6-K | neutral | 2/10 | Helus Pharma Inc. (formerly Cybin Inc.) completed its legal name change to Helus Pharma Inc. effective October 1, 2026, | Oct 1, 2026 |
| XFOR | 144 | neutral | 2/10 | David Kirske, an officer of X4 Pharmaceuticals, filed a Form 144 notice of intent to sell 11,767 common shares (approx. | Oct 1, 2026 |
| MAZE | CLUSTER | bearish | 4/10 | Two Maze Therapeutics insiders, including CEO Jason Coloma, sold a total of $1.07M in open-market sales over a one-week | Oct 1, 2026 |
| AZN | COURT-RULING | neutral | 3/10 | AstraZeneca won a Daubert motion in its ANDA litigation against generic challengers seeking to market a copy of Lynparza | Oct 1, 2026 |
| CGEM | PRESS-RELEASE | bullish | 7/10 | Cullinan Therapeutics announced initiation of an NDA submission to the FDA for zipalertinib plus chemotherapy in first-l | Oct 1, 2026 |
| RVMD | CLUSTER | neutral | 4/10 | Multiple RVMD insiders, including the Chief Development Officer and General Counsel, sold a combined $1.40M in open-mark | Oct 1, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt sold ~$3.8M worth of UTHR shares on 2026-09-30 across 18 open-market trades, while EVP & General C | Oct 1, 2026 |
| AKAN | F-1 | bearish | 7/10 | Akanda Corp. filed an F-1 registration statement for a firm-commitment IPO of up to 4,823,151 common shares (or pre-fund | Oct 1, 2026 |
| PYXS | 8-K | bearish | 7/10 | Pyxis Oncology closed a ~$103M underwritten public offering on October 1, 2026, selling 36M shares, pre-funded warrants | Oct 1, 2026 |
| PTHS | 8-K | neutral | 2/10 | Pelthos Therapeutics held its 2026 Annual Meeting on September 29, 2026, where stockholders approved the new 2026 Equity | Oct 1, 2026 |
| ZNTL | PRESS-RELEASE | neutral | 2/10 | Zentalis Pharmaceuticals granted inducement stock options for 62,000 shares to three newly hired employees under the 202 | Oct 1, 2026 |
| AKTX | DEF 14A | neutral | 4/10 | Akari Therapeutics is holding a general meeting on October 28, 2026, to seek shareholder approval to increase the share | Oct 1, 2026 |
| CELZ | SC 13D | neutral | 4/10 | CEO Timothy Warbington and his entity Creative Acquisition Corp. filed a Schedule 13D disclosing beneficial ownership of | Oct 1, 2026 |
| SRZN | SC 13G | neutral | 4/10 | Commodore Capital LP disclosed a new 7.5% passive stake in Surrozen, Inc. via Schedule 13G, holding 885,000 shares as of | Oct 1, 2026 |